Oncolytic viral therapy and immunotherapy of malignant brain tumors: two potential new approaches of translational research

References

• Katakura R, Yoshimoto T. Epidemiology and Statistical Analysis of Gliomas. In: Suzuki J, ed. Treatment of Gliomas. Tokyo: Springer-Verlag; 1998:3–16.
   Google Scholar
• Dudas SP, Rempel SA. Development, Molecular Genetics, and Gene Therapy. In: Rock JP, Rosenblum ML, Shaw EG, Cairncross JG, eds. The practical management of low-grade primary brain tumors. Philadelphia: Lippincott, Williams & Williams; 1999:193–229.
   Google Scholar
• Preston-Martin S. Epidemiology. In: Berger MS, Wilson CB, eds. The Gliomas. Philadelphia: W. B. Saunders Company; 1999:2–11.
   Google Scholar
• Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252:854–6.
   Google Scholar
• Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1: 938–43.
   Google Scholar
• Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide re-ductase-deficient herpes simplex viral mutant. Cancer Res
   Google Scholar
• Todo T, Rabkin SD, Martuza RL. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic
   Google Scholar
• Sundaresan P, Hunter WD, Martuza RL, Rahkin SD. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 2000; 74: 3832–41.
   PubMed Web of Science ®Google Scholar
• Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999; 73:6319–26.
   PubMed Web of Science ®Google Scholar
• Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999;10:385–93.
   PubMed Web of Science ®Google Scholar
• Todo T, Rahkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999;10:2741–55.
   PubMed Web of Science ®Google Scholar
• Gerher P, Rosenhlum EN. The incidence of complement-fixing antibodies to herpes simplex and herpes-like viruses in man and rhesus monkeys. Proc Soc Exp Biol Med 1968;128: 541–6.
   Google Scholar
• Miller CG, Fraser NW. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor de-struction in a murine intracranial melanoma model. Cancer Res 2000;60:5714–22.
   PubMed Web of Science ®Google Scholar
• Chahlavi A, Rabkin S, Todo T, Sundaresan P, Martuza R. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 1999;6: 1751–8.
   Google Scholar
• Todo T, Rabkin SD, Chahlavi A, Martuza RL. Corticosteroid administration does not affect viral oncolytic activity, hut inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther 1999;10:2869–78.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Kramm CM, Aboody-Guterman KS, Silver JS, Ikeda K, Johnston KM, et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther 1998;5: 809–19.
   Google Scholar
• Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867–74.
   PubMed Web of Science ®Google Scholar
• Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:859–66.
   Google Scholar
• Dietrich PY, Walker PR, Saas P, de Tnbolet N. Immunobiol-ogy of gliomas: new perspectives for therapy. Ann N Y Acad Sci 1997;824:124–40.
   PubMed Web of Science ®Google Scholar
• Fathallah-Shaykh HM, Gao W, Cho M, Herrera MA. Priming in the brain, an immunologically privileged organ, elicits anti-tumor immunity. Int J Cancer 1998;75:266–76.
   Google Scholar
• Parney IF, Hao C, Petruk KC. Glioma immunology and immunotherapy. Neurosurgery 2000; 46: 778–91; discussion 791-2.
   Google Scholar
• Alavi JB, Eck SL. Gene therapy for malignant gliomas. Hematol Oncol Clin North Am 1998;12:617–29.
   PubMed Web of Science ®Google Scholar
• Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, et al. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immu-nity. Cancer Res 2000;60: 2449–57.
   Google Scholar
• Jean WC, Spellman SR, Wallenfriedman MA, Hall WA, Low WC. Interleukin-12-based immunotherapy against rat 9L glioma. Neurosurgery 1998;42:850-6; discussion 856–7.
   Google Scholar
• Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M, et al. Pilot study of local autologous tumor infil-trating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 1999;45:141–57.
   PubMed Web of Science ®Google Scholar
• Roszman T, Elliott L, Brooks W. Modulation of T-cell function by gliomas. Immunol Today 1991;12:370–4.
   Google Scholar
• Fontana A, Hengartner H, de Tribolet N, Weber E. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 1984;132:1837–44.
   PubMed Web of Science ®Google Scholar
• Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 1989;143:3222–9.
   Google Scholar
• Ashley DM, Kong FM, Bigner DD, Hale LP. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apop-tosis in a murine high-grade glioma model. Cancer Res 1998; 58:302–9.
   PubMed Web of Science ®Google Scholar
• Kuppner MC, Hamou MF, Sawamura Y, Bodmer S, de Tribolet N. Inhibition of lymphocyte function by glioblasto-ma-derived transforming growth factor beta 2. J Neurosurg 1989;71:211–7.
   Google Scholar
• Siepl C, Bodmer S, Frei K, MacDonald HR, De Martin R, Hofer E, et al. The glioblastoma-derived T cell suppressor factor/transforming growth factor-beta 2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J Immunol 1988;18:593–600.
   PubMed Web of Science ®Google Scholar
• Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature 1988;334:260–2.
   PubMed Web of Science ®Google Scholar
• Huber D, Philipp J, Fontana A. Protease inhibitors interfere with the transforming growth factor-beta- dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression. J Immunol 1992; 148:277–84.
   Google Scholar
• Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, et al. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 1993;78:944–51.
   PubMed Web of Science ®Google Scholar
• Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996;93:2909–14.
   PubMed Web of Science ®Google Scholar